Genfit (NASDAQ:GNFT) Trading Up 0.5% - What's Next?

Genfit S.A. (NASDAQ:GNFT - Get Free Report) shares rose 0.5% during trading on Wednesday . The company traded as high as $4.33 and last traded at $4.31. Approximately 4,791 shares traded hands during trading, a decline of 67% from the average daily volume of 14,656 shares. The stock had previously closed at $4.29.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Genfit in a research report on Friday, February 7th.

Genfit Stock Down 0.2%

The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. The stock has a 50-day moving average price of $3.80 and a 200-day moving average price of $3.82.

Institutional Investors Weigh In On Genfit

An institutional investor recently bought a new position in Genfit stock. OLD Mission Capital LLC purchased a new position in Genfit S.A. (NASDAQ:GNFT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is owned by institutional investors.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.